Printer Friendly

CHERNE MEDICAL, INC. REDUCES THIRD QUARTER LOSS BY 25 PERCENT AND LOSS FOR NINE-MONTH PERIOD ENDED SEPT. 30, 1991 BY 33 PERCENT

     CHERNE MEDICAL, INC. REDUCES THIRD QUARTER LOSS BY 25 PERCENT
   AND LOSS FOR NINE-MONTH PERIOD ENDED SEPT. 30, 1991 BY 33 PERCENT
    MINNEAPOLIS, Nov. 15 /PRNewswire/ -- Cherne Medical, Inc. (NASDAQ: CHNE), reported a 25 percent decrease in loss for the three months ended Sept. 30, 1991; $435,060 loss versus $627,615 loss, or $(.03) per share versus $(.04) per share for the same period last year and a 33 percent decrease in loss for the nine months ended Sept. 30, 1991; $1,483,925 loss versus $2,080,271, or $(.08) per share versus $(.12) per share for the same period last year.  Revenue growth for the three-month and nine-month periods are also significantly improved; $15,848 compared to $1,720, and $85,552 compared to $2,640, respectively.
    "While improving our revenue generation, I am pleased that our expense control has also contributed to our commitment to reducing our losses," said David L. Printy, chairman, president and CEO.  "Major improvements in the cost of sales and decreases in cost of goods will accelerate the opportunity for profitability as our anticipated sales growth increases over the next 12-month period."
    Most recently the company announced its second contract with The London Clinic and the placement of the Cherne Digital Cardiac Diagnostic System with 100 Medical Plaza Imaging Medical Corp. on the UCLA campus in Los Angeles.  These are responses to the continued exposure and acceptance of Cherne's innovative technology to detect coronary artery disease at rest.
    Earlier this week during a presentation at the 64th Scientific Sessions of the American Heart Association, internationally respected cardiologist of the University of California-San Francisco, Dr. Deedwania, said, "The analysis of electrical disorganization by the electrical heterogeneity index obtained by this 22-lead ECG system provides a new and reliable stress-free test for the detection of clinically important coronary artery disease."
    Cherne Medical manufactures and markets the Cherne Digital Cardiac Diagnostic System (DCDS), a resting, non-invasive, stress-free diagnostic instrument capable of identifying coronary artery disease even when no systems are present.  The common stock of Cherne Medical, Inc. is traded on the national over-the-counter market under the NASDAQ symbol CHNE.
                          CHERNE MEDICAL, INC.
                   CONDENSED STATEMENT OF OPERATIONS
                          Three Months Ended         Nine Months Ended
                         9/30/91      9/30/90      9/30/91      9/30/90
    Revenues             $15,848       $1,720      $85,552       $2,640
    Cost of sales
     and expenses        439,176      706,273    1,601,980    2,233,285
    Operating income
     (loss)             (423,328)    (704,553)  (1,516,428)  (2,230,645)
    Interest and
     miscellaneous
     expenses             29,732      (76,938)      79,500     (150,374)
    Income from
     discontinued
     operations               --           --      112,003          --
    Net income (loss)  $(453,060)   $(627,615) $(1,483,925) $(2,080,271)
    Net income (loss)
     per common share      $(.03)       $(.04)       $(.08)       $(.12)
    Weighted average shares
     outstanding      17,623,899   17,596,616   17,613,640   17,596,616
    -0-                      11/15/91
    /CONTACT:  David L. Printy of Cherne Medical, 612-933-2838/
    (CHNE) CO:  Cherne Medical, Inc. ST:  Minnesota IN:  MTC SU:  ERN KH-JS -- MN013 -- 1741 11/15/91 16:57 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 15, 1991
Words:506
Previous Article:VOPLEX ANNOUNCES THIRD-QUARTER RESULTS
Next Article:THE MISCHER CORPORATION REPORTS THIRD QUARTER RESULTS FOR 1991
Topics:


Related Articles
PAGENET ANNOUNCES THIRD QUARTER RESULTS; REVENUES INCREASE 42 PERCENT, OPERATING CASH FLOW UP 44 PERCENT ON 40 PERCENT INCREASE IN PAGERS
CHERNE MEDICAL ANNOUNCES MAJOR IMPROVEMENTS IN FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
CLASSIC MEDICAL GROUP, INC. REPORTS THIRD QUARTER RESULTS
GULL LABORATORIES REPORTS RECORD NINE-MONTH SALES, REVENUES
S&T BANCORP REPORTS THIRD QUARTER EARNINGS
INTEGRATED HEALTH SERVICES ANNOUNCES THIRD QUARTER RESULTS
MEDAMICUS ANNOUNCES THIRD QUARTER RESULTS
SURGIDYNE, INC. REPORTS THIRD QUARTER AND NINE MONTHS PROFIT
DANNINGER MEDICAL TECHNOLOGY, INC. THIRD QUARTER LOSS
DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES HIGHER THIRD QUARTER REVENUES AND IMPROVED RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters